Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGG 18: 8-week Zepatier in treatment-naive genotype 1b chronic hepatitis C
2017-003710-58Phase 3Active
- Sponsor
- Policlinico Paolo Giaccone
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of grazoprevir and elbasvir in hepatitis C virus infection, sponsored by Policlinico Paolo Giaccone. Primary endpoint: Sustained virologic response at 12 weeks after treatment cessation. Started Jun 2021; status: active.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2017-003710-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003710-58.